This site is intended only for healthcare professionals in UAE, Kuwait, Qatar, Bahrain, Oman.

Search

Menu

Close

Sign In or Register

Log Out Our Medicines Therapy AreasExplore ContentExplore Content

Events

Downloadable materialsVideosLet's ConnectLet's ConnectContact usPfizer medical information

Menu

Close

Maternal ImmunisationMaternal ImmunisationMaternal Immunisation HomepageSafety ProfileDosingOlder AdultsOlder Adults HomepageOlder Adults HomepageSafety ProfileDosingPreparationUseful ResourcesUseful ResourcesOlder AdultsOlder Adults HomepageOlder Adults HomepageSafety ProfileDosingVideosMaterials

Disclaimer: This information is valid only for healthcare professionals in Bahrain, Oman, Qatar & UAE.

Abrysvo™ (Respiratory syncytial virus vaccine) is available, marketed and has a Health Registry only in Bahrain, Oman, Qatar & UAE. The advertising or promotion carried out for Abrysvo™ (Respiratory syncytial virus vaccine) is only directed to health professionals in Bahrain, Oman, Qatar & UAE.

Information on how to access Abrysvo™ (Respiratory syncytial virus vaccine) prescribing information and adverse event reporting can be found at the bottom of the page.
ABRYSVO is a maternal RSV vaccine that can help protect infants
against serious consequences of RSV from birth and through 6
months of life.1

RSV is a leading cause of lower respiratory tract infection (LRTl)-related hospitalisations
in infants in the UAE.2

Infants are most vulnerable to RSV hospitalisation in the first 6 months of life.2
In England, it is estimated that, each year, RSV in infants under 6 months leads to:3

64,000 GP appointments

13,000 RSV associated
hospitalisations

ABRYSVO is a maternal RSV vaccine that can help protect infants against serious
consequences of RSV from birth and through 6 months of life.1

A pregnant woman receives
ABRYSVO during 24-36
weeks of gestation.1

The pregnant woman's
immune system produces
antibodies, which are
passed through the
placenta to the foetus.4

The infant is born with
maternal antibodies helping
to protect against RSV
infection.4

Learn more about RSV & ABRYSVO with 5-minute eModules

eModule 1: Understand RSV disease and the at-risk populationsLoadingeModule 2: What is ABRYSVO?Loading
Safety Profile

Learn more about the safety information of ABRYSVO in pregnant women.

 

 Learn moreLoading
Dosing

Understand more about the dosing, administration and storage of ABRYSVO for maternal patients.
 

 Learn moreLoading
Useful Resources

Explore the ABRYSVO resources section for useful videos and materials.

 VideosLoadingMaterialsLoading
1. Abrysvo™ (Respiratory syncytial virus vaccine) Local Product Document Revision Date: August 2023 for Oman, Qatar, UAE and October 2024 for Bahrain.
2. Saeed B Q, Sharif H A, Adrees A O, Al-Shahrabi R, Fahady K S, Halwani R, Alsalhi N R. Incidence of Respiratory Syncytial Virus Among Young Children in United Arab Emirates. J Nat Sc
Biol Med 2023;14:52-58.
3. Cromer, D. van Hoek, A. J. Newall, A. T. Pollard, A. J. Jit, M. Burden of paediatric respiratory syncytial virus disease and potential effect of different effect immunisation strategies: a
modelling and cost effectiveness analysis for England. Lancet Public Health. 2017. 2(8): e367 -e374.
4. Cinicola, B. et al. The Protective Role of Maternal Immunization in Early Life. Front Pediatr. 2021. 28;9:638871.

Prescribing Information:

Bahrain Prescribing Information
Oman Prescribing Information
Qatar Prescribing Information
UAE Prescribing Information

PP-A1G-BHR-0040

This information is valid only for healthcare professionals in Bahrain, Oman, Qatar & UAE.

Report Adverse Events 

If you'd like to report an adverse event related to a Pfizer Product from Gulf (UAE, Bahrain, Qatar, Oman and Kuwait), please send an email with the adverse event details to: [email protected]

Pfizerpro accountPfizerPro Account

Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.

Sign In or Register

AccountSign Out

Copyright © 2024 Pfizer Gulf FZ LLC. All rights reserved.

 

i- The product information provided in this site is intended only for Healthcare Professionals of UAE, Kuwait, Qatar, Bahrain, Oman.

 

ii- The information contained on this website is offered for educational purposes only and does not represent medical advice, diagnosis, treatment or a professional recommendation. Pfizer will not be responsible for the use or interpretation of the information by the user of the website.

 

iii- The products discussed herein may have a different product labeling than authorized in your country and may not be available in some territories.
 

PP-UNP-BHR-0298
You are now leaving PfizerPro
​
You are leaving the Pfizer Portal - would you like to continue?
 

​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​

You are now leaving Pfizer

You are now leaving Pfizerpro and will be directed to our provider to complete your registration. Any personal information that you may find pre-populated from your Pfizerpro profile, or you may provide, will be governed by our Privacy Policy. Your data will not be used for any other purpose.